7h
Investor's Business Daily on MSNSchrodinger Stock Scores IBD Rating UpgradeSchrodinger stock earned a positive adjustment to its Relative Strength (RS) Rating, from 66 to 73. Please watch the video at ...
12h
Investor's Business Daily on MSNIBD Rating Upgrades: Twist Bioscience Shows Improved Relative Price StrengthOver 100 years of market history reveals that the best stocks typically have an 80 or better RS Rating as they begin their ...
Patients with inflammatory bowel disease remain at higher risk for mental health disorders, but training support staff to ...
1d
News Medical on MSNOral vancomycin induces PSC-IBD remission, driving gut microbiome and metabolic shiftsIn a recent study published in the Journal of Crohn’s and Colitis, researchers showed that oral vancomycin (OV) induces ...
Samsara is the IBD Stock of the Day ahead of its Q4 earnings report due March 6. Samara stock has forged a cup base, rebounding from a sell-off.
Although Stelara and Entyvio demonstrated similar cardiovascular safety profiles among older patients with inflammatory bowel ...
The most common reason for delaying or not receiving care was not getting an appointment when they needed one, cited by 39% of respondents. More than half (56%) of patients reported delays in ...
Persistent care barriers may lead patients with inflammatory bowel disease (IBD) to ration medication or skip doses. The ...
For older adults with inflammatory bowel disease (IBD), there was no significant difference in the risk of major ...
Past research shows that it can be challenging to detect pre-cancerous cells in people with IBD. Researchers from The ...
Queensland has the third highest prevalence of a debilitating bowel disease that impacts 180,000 Australians, costing ...
A recent major OECD report has warned of a looming crisis in the European health workforce. In the third in our series on the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results